Client zone

Johnson and Johnson

Johnson & Johnson’s medical devices and diagnostics division recorded flat sales in Q4 2010 but still managed to outperform the group’s pharma and consumer products businesses.

Medtech revenue for the quarter was $6.3bn, with J&J’s Cordis cardiovascular unit performing particularly badly due to continuing pressures in the drug-eluting stent market.

Cordis reported a 10% drop in sales to $629m on a reported basis, while DePuy posted a 2% drop in revenues to$1.4bn. The company’s Diabetes Care business posted a 2% dip in sales to $644m.

These losses were offset by gains from the firm’s Ethicon (+4% to $1.2bn), Ortho-Clinical Diagnostics (+7% to $536m) and Vision Care (+7% to $659m) businesses. The firm’s Ethicon Endo-Surgery business saw flat sales at $1.3bn.

Leave a Reply

Your email address will not be published. Required fields are marked *

Referral Scheme

Candidate Tools

Join our Mailing list

G2 Academy

Contact Us

We offer a national recruitment service from our Surrey head office, please see contact details below.

Head Office

PM House,
Riverway Estate
Old Portsmouth Rd

T: 01483 910 940

  • 16
  • Aug 2021

Gates & Soros buy UK-based Mologic: A social enterprise to improve global healthcare

Read More

for Us

Find out More